Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abbisko Cayman Limited ( (HK:2256) ) just unveiled an update.
Abbisko Therapeutics has announced promising preliminary results from a Phase II clinical study of its oral PD-L1 inhibitor, ABSK043, in combination with the EGFR inhibitor firmonertinib, for treating non-small cell lung cancer (NSCLC). The study, presented at the ESMO Asia 2025, demonstrated favorable safety and tolerability, with no dose-limiting toxicities observed. The combination showed promising anti-tumor activity, achieving a 71% disease control rate. These findings suggest a potential new treatment strategy for NSCLC patients with EGFR mutations and high PD-L1 expression, addressing a significant unmet need in this patient population.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company specializes in small-molecule inhibitors targeting specific cancer pathways, with a market focus on non-small cell lung cancer (NSCLC) and other oncology indications.
Average Trading Volume: 3,489,925
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.66B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.